GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Intelligent Medicine Acquisition Corp (NAS:IQMDU) » Definitions » Debt-to-Equity

IQMDU (Intelligent Medicine Acquisition) Debt-to-Equity : 0.00 (As of Dec. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Intelligent Medicine Acquisition Debt-to-Equity?

Intelligent Medicine Acquisition's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $0.00 Mil. Intelligent Medicine Acquisition's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $0.00 Mil. Intelligent Medicine Acquisition's Total Stockholders Equity for the quarter that ended in Dec. 2022 was $202.40 Mil. Intelligent Medicine Acquisition's debt to equity for the quarter that ended in Dec. 2022 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Intelligent Medicine Acquisition's Debt-to-Equity or its related term are showing as below:

IQMDU's Debt-to-Equity is not ranked *
in the Diversified Financial Services industry.
Industry Median: 0.16
* Ranked among companies with meaningful Debt-to-Equity only.

Intelligent Medicine Acquisition Debt-to-Equity Historical Data

The historical data trend for Intelligent Medicine Acquisition's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intelligent Medicine Acquisition Debt-to-Equity Chart

Intelligent Medicine Acquisition Annual Data
Trend Dec21 Dec22
Debt-to-Equity
- -

Intelligent Medicine Acquisition Quarterly Data
Feb21 Jun21 Sep21 Dec21 Jun22 Sep22 Dec22
Debt-to-Equity Get a 7-Day Free Trial 55.00 - - - -

Competitive Comparison of Intelligent Medicine Acquisition's Debt-to-Equity

For the Shell Companies subindustry, Intelligent Medicine Acquisition's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Intelligent Medicine Acquisition's Debt-to-Equity Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Intelligent Medicine Acquisition's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Intelligent Medicine Acquisition's Debt-to-Equity falls into.


;
;

Intelligent Medicine Acquisition Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Intelligent Medicine Acquisition's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 202.399
=0.00

Intelligent Medicine Acquisition's Debt to Equity Ratio for the quarter that ended in Dec. 2022 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 202.399
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intelligent Medicine Acquisition  (NAS:IQMDU) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Intelligent Medicine Acquisition Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Intelligent Medicine Acquisition's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Intelligent Medicine Acquisition Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Intelligent Medicine Acquisition Corp (NAS:IQMDU) » Definitions » Debt-to-Equity
Comparable Companies
IFIN WAVC FRW SHCA AVAC OCA ISLE BIOT DWIN TRCA GSHN PSTH XAMS:EPIC ASZ CCYC CVII KAHC DWAC IPOF PBAJ
Traded in Other Exchanges
N/A
Address
9001 Burdette Road, Bethesda, MD, USA, 20817
Website
https://iqmdspac.com
Intelligent Medicine Acquisition Corp is a newly organized blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses.
Executives
Goldman Sachs & Co. Llc 10 percent owner 200 WEST STREET, NEW YORK NY 10282
Goldman Sachs Group Inc 10 percent owner 200 WEST STREET, NEW YORK NY 10282
Saba Capital Management, L.p. 10 percent owner 405 LEXINGTON AVENUE, 58TH FLOOR, NEW YORK NY 10174
Boaz Weinstein 10 percent owner 405 LEXINGTON AVENUE, 58TH FLOOR, NEW YORK NY 10174
Joseph L Schocken director 2800 UNION SQUARE, 600 UNIVERSITY STREET, SEATTLE WA 98101
Kavita Patel director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Jack Hidary director 3 PARK AVENUE, NEW YORK NY 10016
Gregory C Simon director, officer: CEO and CFO 9001 BURDETTE RD., BETHESDA MD 20817
Patience Marime-ball director 9001 BURDETTE RD., BETHESDA MD 20817
Intelligent Medicine Sponsor Llc 10 percent owner 9001 BURDETTE ROAD, BETHESDA MD 20817